Physician profile
Mitchell C Kaplan
NPI 1659332450
$5,540.35
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $528 · 2021: $479 · 2022: $1,293 · 2023: $1,370 · 2024: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,456.83 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.48 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $467.80 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $462.14 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $318.34 | 2019-2024 | Stelara |
| Boston Scientific Corporation | $291.22 | 2020-2024 | Compliance Endokit |
| E.R. Squibb & Sons, L.L.C. | $227.86 | 2021-2023 | Zeposia |
| Genzyme Corporation | $212.10 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $169.09 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $134.97 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $131.01 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $98.63 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $97.51 | 2020-2024 | Suflave |
| Conmed Corporation | $81.86 | 2023 | Conmed Biliary |
| Merck Sharp & Dohme LLC | $76.03 | 2022-2023 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.55 | 2022-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $72.05 | 2024 | |
| Celgene Corporation | $65.37 | 2022-2023 | Zeposia |
| Amgen INC. | $56.19 | 2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $45.67 | 2021-2023 | Gimoti |
| Daiichi Sankyo INC. | $43.57 | 2019 | |
| Pfizer INC. | $39.18 | 2019-2023 | |
| Qol Medical, LLC | $34.11 | 2019-2024 | Sucraid |
| Organon LLC | $28.36 | 2023-2024 | Renflexis |
| Csl Behring | $24.64 | 2019 | |
| Redhill Biopharma INC. | $24.07 | 2023 | |
| Exact Sciences Corporation | $20.66 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.87 | 2024 | Voquezna |
| Allergan, INC. | $17.11 | 2019 | |
| Shire North American Group INC | $16.84 | 2019 | |
| Ardelyx, INC. | $15.71 | 2023 | Ibsrela |
| Shionogi INC | $13.87 | 2019 | |
| Romark Laboratories, Lc | $9.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.